Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis

Neuropharmacology

Volumn 74, Issue , 2013, Pages 48-58

  Wiescholleck, Valentina ^a   Manahan Vaughan, Denise ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Animal model; Dizocilpine; Hippocampus; LTP; MK801; Psychosis; Schizophrenia

Indexed keywords

DIZOCILPINE; GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

COGNITION; COGNITIVE DEFECT; DISEASE MODEL; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG TARGETING; GABAERGIC TRANSMISSION; GLUTAMATERGIC TRANSMISSION; HIPPOCAMPUS; HUMAN; LEARNING DISORDER; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER;

ANIMAL MODEL; DIZOCILPINE; HIPPOCAMPUS; LTP; MK801; PSYCHOSIS; SCHIZOPHRENIA;

ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; HIPPOCAMPUS; MODELS, MOLECULAR; MODELS, NEUROLOGICAL; NEURONAL PLASTICITY; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS;

EID: 84885183587     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.01.001     Document Type: Review

References (141)

1. Abraham, W.C., Mason, S.E., 1988. Effects of the NMDA receptor/channel antagonists CPP and MK801 on hippocampal field potentials and long-term potentiation in anesthetized rats. Brain Res. 462, 40-46.
2. Adell, A., Jiménez-Sánchez, L., López-Gil, X., Romón, T., 2012. Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Schizophr. Bull. 38, 9-14.
3. Akbarian, S., Huang, H.-S., 2006. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res. Rev. 52, 293-304.
4. Andersen, P., Morris, R., Amaral, D., 2007. The Hippocampus Book, first ed. Oxford University Press.
5. Alvarez-Jimenez, M., Gleeson, J.F., Henry, LP., Harrigan, S.M., Harris, M.G., Amminger, G.P., Killackey, E., Yung, A.R., Herrman, H., Jackson, H.J., McGorry, P.D., 2011. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophr. Res. 125, 236-246.
6. Angrist, B., Sathananthan, G., Wilk, S., Gershon, S., 1974. Amphetamine psychosis: behavioral and biochemical aspects. J. Psychiatr. Res. 11, 13-23.
7. Auer, R.N., 1996. Effect of age and sex on N-methyl-D-aspartate antagonist-induced neuronal necrosis in rats. Stroke 27, 743-746.
8. Belforte, J.E., Zsiros, V., Sklar, E.R., Jiang, Z., Yu, G., Li, Y, Quinlan, E.M., Nakazawa, K., 2010. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci. 13, 76-83.
9. Bellack, A.S., Morrison, R.L, Wixted, J.T., Mueser, K.T., 1990. An analysis of social competence in schizophrenia. Br. J. Psychiatry 156, 809-818.
10. Benvenga, M.J., Spaulding, T.C., 1988. Amnesic effect of the novel anticonvulsant MK-801. Pharmacol. Biochem. Behav. 30, 205-207.
11. Bitanihirwe, B.K.Y., Woo, T.-U.W., 2011. Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 35, 878-893.
12. Bitanihirwe, B.K.Y., Lim, M.P., Kelley, J.F., Kaneko, T., Woo, T.U.W, 2009. Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. BMC Psychiatry 9, 71.
13. Braff, D.L., Geyer, M.A., 1990. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 47, 181-188.
14. Bussey, T.J., Holmes, A., Lyon, L., Mar, A.C., McAllister, K.A.L, Nithianantharajah, J., Oomen, CA., Saksida, L.M., 2012. New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology 62, 1191-1203.
15. Carpenter, W.T., Koenig, J.I., 2008. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 33, 2061-2079.
16. Chen, P.E., Errington, M.L., Kneussel, M., Chen, G., Annala, A.J., Rudhard, Y.H., Rast, G.F., Specht, CG., Tigaret, C.M., Nassar, M.A., Morris, R.G.M., Bliss, T.V.P., Schoepfer, R., 2009. Behavioral deficits and subregion-specific suppression of LTP in mice expressing a population of mutant NMDA receptors throughout the hippocampus. Learn. Mem. 16, 635-644.
17. Clineschmidt, B.V., Martin, G.E., Bunting, P.R., 1982. Anticonvulsant activity of (+)-5-Methyl4 0, 11-dihydrodH-dbi enzo[a, d]cyclohepten-5, 10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev. Res., 123-134.
18. Coan, E.J., Saywood, W., Collingridge, G.L., 1987. MK-801 blocks NMDA receptor-mediated synaptic transmission and long term potentiation in rat hippocampal slices. Neurosci. Lett. 80, 111-114.
19. Cochran, S.M., Kennedy, M., McKerchar, CE., Steward, L.J., Pratt, J.A., Morris, B.J., 2003. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28, 265-275.
20. Conrad, CD., 2010. A critical review of chronic stress effects on spatial learning and memory. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 742-755.
21. Corbett, R., Camacho, F., Woods, A.T., Kerman, L.L., Fishkin, R.J., Brooks, K., Dunn, R.W., 1995. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacol. (Berl.) 120, 67-74.
22. Corlett, P.R., Honey, G.D., Krystal, J.H., Fletcher, P.C., 2011. Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology 36, 294-315.
23. Dai, H., Gebhardt, K., Carey, R.J., 1995. Time course effects of MK-801: the relationship between brain neurochemistry and behavior. Brain Res. Bull. 36, 175-180.
24. Dudchenko, P.A., 2004. An overview of the tasks used to test working memory in rodents. Neurosci. Biobehav. Rev. 28, 699-709.
25. Duncan, G.E., Miyamoto, S., Leipzig, J.N., Lieberman, J.A., 1999. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res. 843, 171-183.
26. Dzubay, J.A., Jahr, C.E., 1996. Kinetics of NMDA channel opening. J. Neurosci. 16, 4129-4134.
27. Ellison, G.D., Keys, A.S., 1996. Persisting changes in brain glucose uptake following neurotoxic doses of phencyclidine which mirror the acute effects of the drug. Psychopharmacology (Berl.) 126, 271-274.
28. Eyjolfsson, E.M., Brenner, E., Kondziella, D., Sonnewald, U, 2006. Repeated injection of MK801: an animal model of schizophrenia? Neurochem. Int. 48, 541-546.
29. Farber, N.B., Kim, S.H., Dikranian, K., Jiang, X.P., Heinkel, C, 2002. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol. Psychiatry 7, 32-43.
30. Farber, N.B., Wozniak, D.F., Price, M.T., Labruyere, J., Huss, J., St Peter, H., Olney, J.W, 1995. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol. Psychiatry 38, 788-796.
31. Fix, A.S., Horn, J.W., Wightman, K.A., Johnson, CA., Long, G.G., Storts, R.W., Farber, N., Wozniak, D.F., Olney, J.W, 1993. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp. Neurol. 123, 204-215.
32. Foster, A.C., Wong, E.H., 1987. The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain. Br. J. Pharmacol. 91, 403-409.
33. Fouquet, C., Tobin, C., Rondi-Reig, L., 2010. A new approach for modeling episodic memory from rodents to humans: the temporal order memory. Behav. Brain Res. 215, 172-179.
34. Fraser, C.M., Fisher, A., Cooke, M.J., Thompson, I.D., Stone, T.W., 1997. Purine modulation of dizocilpine effects on spontaneous alternation. Psychopharmacology (Berl.) 130, 334-342.
35. Gao, X.M., Sakai, K., Roberts, R.C., Conley, R.R., Dean, B., Tamminga, C.A., 2000. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry 157, 1141-1149.
36. Gerdeman, G., Lovinger, D.M., 2001. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. 85, 468-471.
37. Geyer, M.A., Krebs-Thomson, K., Braff, D.L., Swerdlow, N.R., 2001. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl.) 156, 117-154.
38. Gleeson, J.F.M., Alvarez-Jimenez, M., Cotton, S.M., Parker, A.G., Hetrick, S., 2010. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr. Res. 119, 79-88.
39. Gloveli, T., Iserhot, C., Schmitz, D., Castrén, E., Behr, J., Heinemann, U., 1997. Systemic administration of the phencyclidine compound MK-801 affects stimulus-induced field potentials selectively in layer III of rat medial entorhinal cortex. Neurosci. Lett. 221, 93-96.
40. Gold, J.M., Harvey, P.D., 1993. Cognitive deficits in schizophrenia. Psychiatr. Clin. North Am. 16, 295-312.
41. Gordon, J.A., 2010. Testing the glutamate hypothesis of schizophrenia. Nat. Neurosci. 13, 2-4.
42. Goulart, B.K., de Lima, M.N.M., de Farias, C.B., Reolon, G.K., Almeida, V.R., Quevedo, J., Kapczinski, F., Schröder, N., Roesler, R., 2010. Ketamine impairs recognition memory consolidation and prevents learning-induced increase in hippocampal brain-derived neurotrophic factor levels. Neuroscience 167, 969-973.
43. Gray, L., McOmish, C.E., Scarr, E., Dean, B., Hannan, A.J., 2009. Sensitivity to MK-801 in phospholipase C-β1 knockout mice reveals a specific NMDA receptor deficit. Int. J. Neuropsychopharmacol. 12, 917-928.
44. Green, M.F., 1996. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153, 321-330.
45. Grunze, H.C., Rainnie, D.G., Hasselmo, M.E., Barkai, E., Hearn, E.F., McCarley, R.W., Greene, R.W., 1996. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 16, 2034-2043.
46. Gunn, A.J., Williams, C.E., Bennet, L., Cook, C.J., Gluckman, P.D., 1988. Perinatal cerebral asphyxia: pharmacological intervention. Fetal Ther. 3, 98-107.
47. Halliwell, R.F., Peters, J.A., Lambert, J.J., 1989. The mechanism of action and pharmacological specificity of the anticonvulsant NMDA antagonist MK-801: a voltage clamp study on neuronal cells in culture. Br. J. Pharmacol. 96, 480-494.
48. Harris, L.W., Sharp, T., Gartlon, J., Jones, D.N.C., Harrison, P.J., 2003. Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur. J. Neurosci. 18, 1706-1710.
49. Harrison, P.J., 1999. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122 (Pt 4), 593-624.
50. Hashimoto, K., Tomitaka, S., Bi, Y., Narita, N., Minabe, Y., Iyo, M., 1997. Rolipram, a selective phosphodiesterase type-IV inhibitor, prevents induction of heat shock protein HSP-70 and hsp-70 mRNA in rat retrosplenial cortex by the NMDA receptor antagonist dizocilpine. Eur. J. Neurosci. 9, 1891-1901.
51. Hashimoto, K., Tomitaka, S., Narita, N., Minabe, Y., Iyo, M., Fukui, S., 1996. Induction of heat shock protein (HSP)-70 in posterior cingulate and retrosplenial cortex of rat brain by dizocilpine and phencyclidine: lack of protective effects of sigma receptor ligands. Addict. Biol. 1, 61-70.
52. Hashimoto, T., Volk, D.W., Eggan, S.M., Mirnics, K., Pierri, J.N., Sun, Z., Sampson, A.R., Lewis, D.A., 2003. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 23, 6315-6326.
53. Heale, V., Harley, C., 1990. MK-801 and AP5 impair acquisition, but not retention, of the Morris milk maze. Pharmacol. Biochem. Behav. 36, 145-149.
54. Healy, D.J., Meador-Woodruff, J.H., 1996. Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesocorticolimbic systems. Brain Res. 708, 38-44.
55. Hoffman, D.C., 1992. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm. Gen. Sect. 89, 1-10.
56. Horváth, Z.C., Czopf, J., Buzsáki, G., 1997. MK-801-induced neuronal damage in rats. Brain Res. 753, 181-195.
57. Huettner, J.E., Bean, B.P., 1988. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proc. Natl. Acad. Sci. U.S.A. 85, 1307-1311.
58. Huh, K.H., Wenthold, R.J., 1999. Turnover analysis of glutamate receptors identifies a rapidly degraded pool of the N-methyl-D-aspartate receptor subunit, NR1, in cultured cerebellar granule cells. J. Biol. Chem. 274, 151-157.
59. Insel, T.R., 2010. Rethinking schizophrenia. Nature 468, 187-193.
60. Javitt, D.C., Zukin, S.R., 1989. Interaction of [3H]MK-801 with multiple states of the N-methyl-D-aspartate receptor complex of rat brain. Proc. Natl. Acad. Sci. U.S.A. 86, 740-744.
61. Javitt, D.C., Zukin, S.R., 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308.
62. Jentsch, J.D., Roth, R.H., 1999. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225.
63. Jodo, E., Suzuki, Y., Katayama, T., Hoshino, K.-Y., Takeuchi, S., Niwa, S.-I., Kayama, Y., 2005. Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway. Cereb. Cortex 15, 663-669.
64. Jones, K.W., Bauerle, L.M., DeNoble, V.J., 1990. Differential effects of sigma and phencyclidine receptor ligands on learning. Eur. J. Pharmacol. 179, 97-102.
65. Kapur, S., Mamo, D., 2003. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 1081-1090.
66. Kehrer, C., Dugladze, T., Maziashvili, N., Wójtowicz, A., Schmitz, D., Heinemann, U., Gloveli, T., 2007. Increased inhibitory input to CA1 pyramidal cells alters hippocampal gamma frequency oscillations in the MK-801 model of acute psychosis. Neurobiol. Dis. 25, 545-552.
67. Kim, J.S., Kornhuber, H.H., Schmid-Burgk, W., Holzmüller, B., 1980. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20, 379-382.
68. Kinney, J.W., Davis, C.N., Tabarean, I., Conti, B., Bartfai, T., Behrens, M.M., 2006. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J. Neurosci. 26, 1604-1615.
69. Kittelberger, K., Hur, E.E., Sazegar, S., Keshavan, V., Kocsis, B., 2012. Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia. Brain Struct. Funct. 217, 395-409.
70. Kochhar, A., Zivin, J.A., Lyden, P.D., Mazzarella, V., 1988. Glutamate antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia. Arch. Neurol. 45, 148-153.
71. Kornhuber, J., Weller, M., 1997. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry 41, 135-144.
72. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B., Charney, D.S., 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214.
73. Lahti, A.C., Weiler, M.A., Tamara Michaelidis, B.A., Parwani, A., Tamminga, C.A., 2001. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25, 455-467.
74. Lane, H.-Y., Lin, C.-H., Huang, Y.-J., Liao, C.-H., Chang, Y.-C., Tsai, G.E., 2010. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 13, 451-460.
75. Lasley, S.M., Gilbert, M.E., 1996. Presynaptic glutamatergic function in dentate gyrus in vivo is diminished by chronic exposure to inorganic lead. Brain Res. 736, 125-134.
76. Lee, S.H., Kim, K.-R., Ryu, S.-Y., Son, S., Hong, H.S., Mook-Jung, I., Lee, S.-H., Ho, W.-K., 2012. Impaired short-term plasticity in mossy fiber synapses caused by mitochondrial dysfunction of dentate granule cells is the earliest synaptic deficit in a mouse model of Alzheimer's disease. J. Neurosci. 32, 5953-5963.
77. Lévénés, C., Daniel, H., Soubrié, P., Crépel, F., 1998. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J. Physiol. (Lond.) 510 (Pt 3), 867-879.
78. Li, J.-T., Su, Y.-A., Guo, C.-M., Feng, Y., Yang, Y., Huang, R.-H., Si, T.-M., 2011. Persisting cognitive deficits induced by low-dose, subchronic treatment with MK-801 in adolescent rats. Eur. J. Pharmacol. 652, 65-72.
79. Lieberman, J.A., Kane, J.M., Alvir, J., 1987. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl.) 91, 415-433.
80. Lindén, A.M., Väsäinen, J., Wong, G., Castrén, E., 1997. NMDA receptor 2C subunit is selectively decreased by MK-801 in the entorhinal cortex. Eur. J. Pharmacol. 319, R1-R2.
81. Lindén, A.M., Väsänen, J., Storvik, M., Lakso, M., Korpi, E.R., Wong, G., Castrén, E., 2001. Uncompetitive antagonists of the N-methyl-D-aspartate (NMDA) receptors alter the mRNA expression of proteins associated with the NMDA receptor complex. Pharmacol. Toxicol. 88, 98-105.
82. Lindsley, C.W., Shipe, W.D., Wolkenberg, S.E., Theberge, C.R., Williams, D.L., Sur, C., Kinney, G.G., 2006. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Top. Med. Chem. 6, 771-785.
83. Lipska, B.K., Weinberger, D.R., 2000. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23, 223-239.
84. Lisman, J.E., Coyle, J.T., Green, R.W., Javitt, D.C., Benes, F.M., Heckers, S., Grace, A.A., 2008. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31, 234-242.
85. Lukoyanov, N.V., Paula-Barbosa, M.M., 2000. A single high dose of dizocilpine produces long-lasting impairment of the water maze performance in adult rats. Neurosci. Lett. 285, 139-142.
86. MacDonald, J.F., Bartlett, M.C., Mody, I., Pahapill, P., Reynolds, J.N., Salter, M.W., Schneiderman, J.H., Pennefather, P.S., 1991. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J. Physiol. (Lond.) 432, 483-508.
87. Malone, D.T., Hill, M.N., Rubino, T., 2010. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br. J. Pharmacol. 160, 511-522.
88. Manahan-Vaughan, D., von Haebler, D., Winter, C., Juckel, G., Heinemann, U., 2008a. A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 18, 125-134.
89. Manahan-Vaughan, D., Wildförster, V., Thomsen, C., 2008b. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). Eur. J. Neurosci. 28, 1342-1350.
90. Marcotte, E.R., Pearson, D.M., Srivastava, L.K., 2001. Animal models of schizophrenia: a critical review. J. Psychiatry Neurosci. 26, 395-410.
91. McGlashan, T.H., 2006. Is active psychosis neurotoxic? Schizophr. Bull. 32, 609-613.
92. Mesa-Castillo, S., 2001. Estudio ultraestructural del lóbulo temporal y de la sangre periférica en pacientes esquizofrénicos. Rev. Neurol. 33, 619-623.
93. Moghaddam, B., 2003. Bringing order to the glutamate chaos in schizophrenia. Neuron 40, 881-884.
94. Mohn, A.R., Gainetdinov, R.R., Caron, M.G., Koller, B.H., 1999. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98, 427-436.
95. Monyer, H., Burnashev, N., Laurie, D.J., Sakmann, B., Seeburg, P.H., 1994. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12, 529-540.
96. Mori, H., Mishina, M., 1995. Structure and function of the NMDA receptor channel. Neuropharmacology 34, 1219-1237.
97. Murase, S., Mathé, J.M., Grenhoff, J., Svensson, T.H., 1993. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. J. Neural Transm. Gen. Sect. 91, 13-25.
98. Murray, T.K., Ridley, R.M., 1997. The effect of dizocilpine (MK-801) on conditional discrimination learning in the rat. Behav. Pharmacol. 8, 383-388.
99. Mutlu, O., Ulak, G., Celikyurt, I.K., Akar, F.Y., Erden, F., 2011. Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice. Pharmacol. Biochem. Behav. 98, 398-404.
100. Olney, J.W., Farber, N.B., 1995. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13, 335-345.
101. Olney, J.W., Labruyere, J., Price, M.T., 1989. Pathological changes induced in cerebrocortical neuronsbyphencyclidine and related drugs. Science 244, 1360-1362.
102. Olney, J.W., Labruyere, J., Wang, G., Wozniak, D.F., Price, M.T., Sesma, M.A., 1991. NMDA antagonist neurotoxicity: mechanism and prevention. Science 254, 1515-1518.
103. Paulson, L., Martin, P., Persson, A., Nilsson, C.L., Ljung, E., Westman-Brinkmalm, A., Eriksson, P.S., Blennow, K., Davidsson, P., 2003. Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. J. Neurosci. Res. 71, 526-533.
104. Peled, A., 2005. Plasticity imbalance in mental disorders the neuroscience of psychiatry: implications for diagnosis and research. Med. Hypotheses 65, 947-952.
105. Perry, T.L., Kish, S.J., Buchanan, J., Hansen, S., 1979. Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet 1, 237-239.
106. Pilowsky, L.S., Bressan, R.A., Stone, J.M., Erlandsson, K., Mulligan, R.S., Krystal, J.H., Ell, P.J., 2006. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol. Psychiatry 11, 118-119.
107. Robinson, D.G., Woerner, M.G., McMeniman, M., Mendelowitz, A., Bilder, R.M., 2004. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 161, 473-479.
108. Romón, T., Mengod, G., Adell, A., 2011. Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia. Psychopharmacology (Berl.) 217, 231-238.
109. Rosenfeld, M., Brenner-Lavie, H., Ari, S.G.-B., Kavushansky, A., Ben-Shachar, D., 2011. Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. Biol. Psychiatry 69, 980-988.
110. Rosenmund, C., Clements, J.D., Westbrook, G.L., 1993. Nonuniform probability of glutamate release at a hippocampal synapse. Science 262, 754-757.
111. Rujescu, D., Bender, A., Keck, M., Hartmann, A.M., Ohl, F., Raeder, H., Giegling, I., Genius, J., McCarley, R.W., Möller, H.-J., Grunze, H., 2006. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol. Psychiatry 59, 721-729.
112. Rung, J.P., Carlsson, A., Rydén Markinhuhta, K., Carlsson, M.L., 2005. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 827-832.
113. Sams-Dodd, F., 1999. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. 10, 59-90.
114. Sams-Dodd, F., 2004. (+) MK-801 and phencyclidine induced neurotoxicity do not cause enduring behaviours resembling the positive and negative symptoms of schizophrenia in the rat. Basic Clin. Pharmacol. Toxicol. 95, 241-246.
115. Schretlen, D.J., Cascella, N.G., Meyer, S.M., Kingery, L.R., Testa, S.M., Munro, C.A., Pulver, A.E., Rivkin, P., Rao, V.A., Diaz-Asper, C.M., Dickerson, F.B., Yolken, R.H., Pearlson, G.D., 2007. Neuropsychological functioning in bipolar disorder and schizophrenia. Biol. Psychiatry 62, 179-186.
116. Seeman, P., 1987. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1, 133-152.
117. Shen, M., Piser, T.M., Seybold, V.S., Thayer, S.A., 1996. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16, 4322-4334.
118. Shiotani, M., Nakano, K., Yamauchi, E., Oda, Y., Hosokawa, S., Aoki, T., 2011. Proteomic analysis for neuronal vacuolation induced by MK-801 in rat retrosplenial cortex. J. Toxicol. Sci. 36, 131-133.
119. Sibley, D.R., 1999. New insights into dopaminergic receptor function using anti-sense and genetically altered animals. Annu. Rev. Pharmacol. Toxicol. 39, 313-341.
120. Somerville, S.M., Conley, R.R., Roberts, R.C., 2012. Striatal mitochondria in subjects with chronic undifferentiated vs. chronic paranoid schizophrenia. Synapse 66, 29-41.
121. Stone, W.S., Hsi, X., 2011. Declarative memory deficits and schizophrenia: problems and prospects. Neurobiol. Learn. Mem. 96, 544-552.
122. Talukder, I., Borker, P., Wollmuth, LP., 2010. Specific sites within the ligand-binding domain and ion channel linkers modulate NMDA receptor gating. J. Neurosci. 30, 11792-11804.
123. Tamminga, CA., 2009. Principle of the pharmacotherapy of schizophrenia. In: Neurobiology of Mental Illness. Oxford University Press, pp. 329-347.
124. Tiedtke, P.I., Bischoff, C, Schmidt, W.J., 1990. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural Transm. Gen. Sect. 81, 173-182.
125. Tsien, J.Z., Huerta, P.T., Tonegawa, S., 1996. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 87, 1327-1338.
126. van der Staay, F.J., 2006. Animal models of behavioral dysfunctions: basic concepts and classifications, and an evaluation strategy. Brain Res. Rev. 52, 131-159.
127. van der Staay, F.J., Rutten, K., Erb, C, Blokland, A., 2011. Effects of the cognition impairer MK-801 on learning and memory in mice and rats. Behav. Brain Res. 220, 215-229.
128. van Rossum, J.M., 1966. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int. Pharmacodyn. Ther. 160, 492-494.
129. Verma, A., Moghaddam, B., 1996. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16, 373-379.
130. Vezzani, A., Serafini, R., Stasi, M.A., Caccia, S., Conti, I., Tridico, R.V., Samanin, R., 1989. Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. J. Pharmacol. Exp. Ther. 249, 278-283.
131. Wedzony, K., Czyrak, A., Mackowiak, M., Fijai, K., 1996. The impact of a competitive and a non-competitive NMDA receptor antagonist on dopaminergic neurotransmission in the rat ventral tegmental area and substantia nigra. Naunyn Schmiedebergs Arch. Pharmacol. 353, 517-527.
132. Wedzony, K., Klimek, V., Golembiowska, K., 1993. MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res. 622, 325-329.
133. Weickert, CS., Fung, S.J., Catts, V.S., Schofield, P.R., Allen, K.M., Moore, L.T., Newell, K.A., Pellen, D., Huang, X.-F., Catts, S.V., Weickert, T.W., 2012. Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol. Psychiatry.
134. Wiescholleck, V., Manahan-Vaughan, D., 2012a. PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosis. Transl. Psychiatry 2, e89.
135. Wiescholleck, V., Manahan-Vaughan, D., 2012b. An acute Mk801-induced schizophreniform psychotic episode is followed by chronic and persistent deficits in hippocampal long-term potentiation and memory. FENS Forum conference, 2012. Available at: http://fens.ekonnect.co/FENS-331/poster-34800/ program.aspx (accessed 15.11.12).
136. Wöhrl, R., Eisenach, S., Manahan-Vaughan, D., Heinemann, U., Von Haebler, D., 2007. Acute and long-term effects of MK-801 on direct cortical input evoked homosynaptic and heterosynaptic plasticity in the CA1 region of the female rat. Eur. J. Neurosci. 26, 2873-2883.
137. Wong, E.H., Kemp, JA, Priestley, T., Knight, A.R., Woodruff, G.N., Iversen, LL, 1986. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. U.S.A. 83, 7104-7108.
138. Wozniak, D.F., Brosnan-Watters, G., Nardi, A., McEwen, M., Corso, T.D., Olney, J.W, Fix, A.S., 1996. MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning. Brain Res. 707, 165-179.
139. Zhang, J., Chiodo, L.A., Freeman, A.S., 1992. Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons. Brain Res. 590, 153-163.
140. Zhang, Z., Sun, J., Reynolds, G.P., 2002. A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. Chin. Med. J. 115, 819-823.
141. Zou, H., Zhang, C, Xie, Q., Zhang, M., Shi, J., Jin, M., Yu, L., 2008. Low dose MK-801 reduces social investigation in mice. Pharmacol. Biochem. Behav. 90, 753-757.